NewsXbrane Biopharma informs about ongoing negotiations concerning out-licensing of Spherotide to China

Xbrane Biopharma AB (publ) (“Xbrane” or the “Company”) continue its negotiations concerning out-licensing of sales and marketing rights of Spherotide in China and expect to enter a final agreement during first quarter of 2018.

In accordance with what has previously been communicated in press releases, interim reports and presentations, Xbrane is in discussions and negotiations with potential partners regarding out-licensing of Spherotide and Xlucane. One of these negotiations concerns out-licensing of the rights to sell and market Spherotide in China to a large Chinese company.

Final negotiation for the agreement took place during the Chinese partner’s visit in Sweden and in Italy in December. The Company has earlier announced that the final agreement was expected to be entered during 2017 but can now inform that the entering of the agreement is expected to take place during the first quarter of 2018.

For further information, please contact:
Martin Åmark, CEO, Xbrane Biopharma AB
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com

Susanna Helgesen, CFO/IR, Xbrane Biopharma AB
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com